Citations

Showing 10 of 108104 citations.

AAPM Medical Physics Practice Guideline 12.a: Fluoroscopy dose management
Fisher, Ryan , Berkowitz, Lindsey K., Christianson, Olav, Dave, Jaydev K. , DeWeese, Lindsay , Harris, Nichole, Jafari, Mary Ellen, Jones, A. Kyle , Kobistek, Robert J., Loughran, B, Marous, Loren, Miller, Donald L. , Schueler, Beth A. , Schwarz, Bryan C. , Springer, A., DeWeese, Lindsay , Schueler, Beth, Schwarz, Bryan C , Applegate, Kimberly E. , Wunderle, Kevin

Mayo Clinic

Journal of Applied Clinical Medical Physics | February 17, 2022 | Volume: 23 | Issue: 3 | Pages: No page available

10.1002/acm2.13526 | PMID 35174964 Get It

Clinical Activity of Single Dose Systemic Oncolytic VSV Virotherapy in Patients with Relapsed Refractory T-Cell Lymphoma
Peng, Kah Whye, Witzig, Thomas E. , Broski, Stephen M. , Villasboas, José C. , Patnaik, Mrinal M. , Leung, Nelson , Ansell, Stephen M. , Zhang, Lianwen , Brunton, Bethany, Giers, Marissa, Ginos, Brenda, Dueck, Amylou C. , Geyer, Susan M. , Warsame, Rahma , Hayman, Suzanne R. , Dingli, David , Kumar, Shaji , Bergsagel, P. Leif , Kourelis, Taxiarchis , Kapoor, Prashant , Kyle, Robert A. , Lin, Yi , Siddiqui, Mustaqeem , Fonder, Amie , Hobbs, Miriam, Hwa, Yi L. , Naik, Shruthi , Russell, Stephen J. , Lacy, Martha Q. , Bergsagel, P. Leif , Witzig, T.E. , Broski, Stephen M , Villasboas, Jose Caetano , Paludo, Jonas , Patnaik, Mrinal , Dispenzieri, Angela , Leung, Nelson , Buadi, Francis K , Bennani, N Nora , Balakrishnan, Baskar , Dueck, A. C. , Gertz, Morie A , Warsame, Rahma , Kumar, Shaji K , Munoz, Javier L, Kourelis, Taxiarchis , Muchtar, E , Siddiqui, Mustaqeem A , Fonder, Amie , Russell, Stephen J , Lacy, Martha Q , Dingli, David , Lin, Yi , Cook, Joselle , Paludo, Jonas , Rajkumar, S. Vincent , Dispenzieri, Angela , Buadi, Francis K. , Bennani, N. Nora , Packiriswamy, Nandakumar , Balakrishnan, Baskar , Gertz, Morie A. , Go, Ronald S. , Muñoz, Javier , Gonsalves, Wilson I. , Muchtar, Eli

Mayo Clinic

Blood Advances | February 17, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1182/bloodadvances.2021006631 | PMID 35175355 Get It

Clinical success with intravenous (IV) oncolytic virotherapy (OV) has to date been anecdotal. Here, we conducted a phase 1 clinical trial of systemic OV therapy and investigated the mechanisms of action in responding T-cell lymphoma (TCL) patients. A single IV dose of VSV-IFNβ-NIS was administered to patients with relapsed refractory hematologic malignancies to determine safety and efficacy across 4 dose levels (DL). Correlative studies were undertaken to evaluate viremia, virus shedding, virus replication and immune responses. Fifteen patients received VSV-IFNβ-NIS (7 multiple myeloma, 7 TCL, 1 acute myeloid leukemia); 3 patients were treated at each DL1 through DL3 (0.05, 0.17, and 0.5 x 1011 TCID50), and 6 at DL4 (1.7 x 1011 TCID50). There were no dose limiting toxicities. 3 of 7 patients with TCL had RECIST responses: a 3-month PR at DL2, a 6-month PR and a durable CR ongoing at 20 months at DL4. Viremia peaked at the end of infusion and no infectious virus shedding was detected. Plasma interferon-β levels, a biomarker of VSV-IFNβ-NIS replication, peaked between 4h and 48h post infusion. The patient with CR had robust viral replication with increased ell free DNA in her plasma, a very high peak IFNβ level of 18,213 pg/ml, a strong anti-VSV neutralizing antibody response, and increased numbers of tumor reactive T-cells. VSV-IFNβ-NIS as a single agent was effective in patients with TCL resulting in durable disease remissions in heavily pretreated patients. Correlative analyses suggest that responses may be due to a combination of direct oncolytic tumor destruction and immune-mediated tumor control. Further clinical testing is warranted. (This trial is registered at www.clinicaltrials.gov as NCT03017820).
Molecular Biomarker Testing for the Diagnosis of Diffuse Gliomas
Brat, Daniel J., Aldape, Kenneth, Bridge, Julia A., Canoll, Peter, Colman, Howard, Hameed, Meera R., Harris, Brent T., Hattab, Eyas M., Huse, Jason T., Jenkins, Robert B., Lopez-Terrada, Dolores H., McDonald, William C., Rodriguez, Fausto J., Souter, Lesley H., Colasacco, Carol, Thomas, Nicole E., Yount, Michelle Hawks, Bent, Martin J. van den, Perry, Arie, Bent, Martin J. van den , Colasacco, Carol , van den Bent, Martin J , Brat, Daniel J., Aldape, Kenneth, Bridge, Julia A., Canoll, Peter, Colman, Howard, Hameed, Meera R., Harris, Brent T., Hattab, Eyas M. , Huse, Jason T., Jenkins, Robert B., Lopez-Terrada, Dolores H., McDonald, William C., Rodriguez, Fausto J., Souter, Lesley H., Colasacco, Carol, Thomas, Nicole E., Yount, Michelle Hawks, Perry, Arie

Mayo Clinic

Archives of Pathology & Laboratory Medicine | February 17, 2022 | Volume: 146 | Issue: 5 | Pages: 547-574

10.5858/arpa.2021-0295-cp | PMID 35175291 Get It

Context.— The diagnosis and clinical management of patients with diffuse gliomas (DGs) have evolved rapidly over the past decade with the emergence of molecular biomarkers that are used to classify, stratify risk, and predict treatment response for optimal clinical care. Objective.— To develop evidence-based recommendations for informing molecular biomarker testing for pediatric and adult patients with DGs and provide guidance for appropriate laboratory test and biomarker selection for optimal diagnosis, risk stratification, and prediction. Design.— The College of American Pathologists convened an expert panel to perform a systematic review of the literature and develop recommendations. A systematic review of literature was conducted to address the overarching question, “What ancillary tests are needed to classify DGs and sufficiently inform the clinical management of patients?” Recommendations were derived from quality of evidence, open comment feedback, and expert panel consensus. Results.— Thirteen recommendations and 3 good practice statements were established to guide pathologists and treating physicians on the most appropriate methods and molecular biomarkers to include in laboratory testing to inform clinical management of patients with DGs. Conclusions.— Evidence-based incorporation of laboratory results from molecular biomarker testing into integrated diagnoses of DGs provides reproducible and clinically meaningful information for patient management.
A wearable cardioverter defibrillator with a low false alarm rate
Poole, Jeanne E. , Gleva, Marye J. , Birgersdotter‐Green, Ulrika , Branch, Kelley R. , Salam, Tariq , Crawford, Thomas , Willcox, Mark E. , Sridhar, Arun Mahankali, Mikdadi, Ghiath, Beinart, Sean C., Cha, Yong‐Mei , Russo, Andrea M. , Rowbotham, Ron, Sullivan, Joseph, Gustavson, Laura , Kivilaid, Kaisa, Salam, Tariq , Cha, Yong-Mei , Doshi, Rahul N.

Mayo Clinic

Journal of Cardiovascular Electrophysiology | February 17, 2022 | Volume: 33 | Issue: 5 | Pages: 831-842

10.1111/jce.15417 | PMID 35174572 Get It

AbstractIntroductionA wearable cardioverter defibrillator (WCD) is indicated in appropriate patients to reduce the risk for sudden cardiac death. Challenges for patients wearing a WCD have been frequent false shock alarms primarily due to electrocardiogram noise and wear discomfort. The objective of this study was to test a contemporary WCD designed for reduced false shock alarms and improved comfort.MethodsOne hundred and thirty patients with left ventricular ejection fraction ≤40% and an active implantable cardioverter defibrillator (ICD) were fitted with the ASSURE WCD (Kestra Medical Technologies) and followed for 30 days. WCD detection was enabled and shock alarm markers recorded, but shocks and shock alarms were disabled. All WCD episodes and ICD ventricular tachycardia/ventricular fibrillation (VT/VF) episodes were adjudicated. The primary endpoint was the false‐positive shock alarm rate with a performance goal of 1 every 3.4 days (0.29 per patient‐day).ResultsOf 163 WCD episodes, 4 were VT/VF and 159 non‐VT/VF (121 rhythms with noise, 32 uncertain with noise, 6 atrial flutter without noise). Only three false‐positive shock alarm markers were recorded; one false‐positive shock alarm every 1333 patient‐days (0.00075 per patient‐day, 95% confidence interval: 0.00015–0.00361; p < .001). No ICD recorded VT/VF episodes meeting WCD detection criteria (≥170 bpm for ≥20 s) were missed by the WCD during 3501 patient‐days of use. Median wear was 31.0 days (interquartile range [IQR] 2.0) and median daily use 23.0 h (IQR 1.7). Adverse events were mostly mild: skin irritation (19.4%) and musculoskeletal discomfort (8.5%).ConclusionThe ASSURE WCD demonstrated a low false‐positive shock alarm rate, low patient‐reported discomfort, and no serious adverse events.
Comparative assessment of allergic reactions to COVID‐19 vaccines in Europe and the United States
Hatziantoniou, Sophia , Anastassopoulou, Cleo , Lampropoulou, Vicky , Maltezou, Helena C. , Andreakos, Evangelos , Poland, Gregory A. , Tsakris, Athanasios , Poland, Gregory A

Mayo Clinic

Allergy | February 17, 2022 | Volume: 77 | Issue: 5 | Pages: 1630-1633

10.1111/all.15257 | PMID 35174502 Get It

A Review of Coronaviruses Associated With Kawasaki Disease: Possible Implications for Pathogenesis of the Multisystem Inflammatory Syndrome Associated With COVID-19
Shahbaz, Fatima Farrukh , Abdullah, Umair, Ukrani, Ronika Devi , Sohail, Marium, Ukrani, Ronika Devi , Martins, Russell Seth , Umair, Abdullah, Jabeen, Kauser , Sohail, M Rizwan, Khan, Erum

Mayo Clinic

Clinical Medicine Insights: Pediatrics | February 17, 2022 | Volume: 16 | Issue: No issue available | Pages: No page available

10.1177/11795565221075319 | PMID 35197719 Get It

Multisystem Inflammatory Syndrome in Children (MIS-C), representing a new entity in the spectrum of manifestations of COVID-19, bears symptomatic resemblance with Kawasaki Disease (KD). This review explores the possible associations between KD and the human coronaviruses and discusses the pathophysiological similarities between KD and MIS-C and proposes implications for the pathogenesis of MIS-C in COVID-19. Since 2005, when a case-control study demonstrated the association of a strain of human coronavirus with KD, several studies have provided evidence regarding the association of different strains of the human coronaviruses with KD. Thus, the emergence of the KD-like disease MIS-C in COVID-19 may not be an unprecedented phenomenon. KD and MIS-C share a range of similarities in pathophysiology and possibly even genetics. Both share features of a cytokine storm, leading to a systemic inflammatory response and oxidative stress that may cause vasculitis and precipitate multi-organ failure. Moreover, antibody-dependent enhancement, a phenomenon demonstrated in previous coronaviruses, and the possible superantigenic behavior of SARS-CoV-2, possibly may also contribute toward the pathogenesis of MIS-C. Lastly, there is some evidence of complement-mediated microvascular injury in COVID-19, as well as of endotheliitis. Genetics may also represent a possible link between MIS-C and KD, with variations in FcγRII and IL-6 genes potentially increasing susceptibility to both conditions. Early detection and treatment are essential for the management of MIS-C in COVID-19. By highlighting the potential pathophysiological mechanisms that contribute to MIS-C, our review holds important implications for diagnostics, management, and further research of this rare manifestation of COVID-19.
CDK7 inhibition augments the response against multidrug chemotherapy in pancreatic cancer
Zeng, Siyuan , Lan, Bin , Ren, Xiaofan, Zhang, Shuman , Schreyer, Daniel , Eckstein, Markus , Kutschick, Isabella, Pfeffer, Susanne, Grützmann, Robert , Zeng, Siyuan, Yang, Hai , Britzen‐Laurent, Nathalie , Dahl, Andreas , Mukhopadhyay, Debabrata , Chang, David K. , Bailey, Peter J. , Biankin, Andrew V. , Pilarsky, Christian

Mayo Clinic

No container title available | February 16, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-1333955/v1 Get It

Abstract Background: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with a dismal prognosis. Although combined treatment with gemcitabine and albumin-bound paclitaxel has improved the prognosis of PDAC, both intrinsic and acquired chemoresistance cloud the outcomes. Hence, there is an urgent need to explore new therapeutic targets and formulate innovative strategies for the more effective treatment of PDAC.Methods: We transduced pancreatic cancer cells with a protein kinase library, and transfected cells were selected by puromycin treatment, followed by continuous exposure to vehicle control or gemcitabine/paclitaxel chemotherapy for 21 days. Next-generation sequencing as well as MAGeCK-VISPR analysis were performed to the identify candidate genes. Finally, we used the CRISPR-Cas9 to knockout the target gene, confirming that it is a viable target for overcoming chemoresistance in vivo and in vitro.Results: We identified several cell cycle checkpoint kinases and DNA damage-related kinases as targets for overcoming chemoresistance. Among them, cyclin-dependent kinase 7 (CDK7) ranked highly in both screenings. We demonstrated that both gene knockout and pharmacological inhibition of CDK7 by THZ1 result in cell cycle arrest, apoptosis induction. Furthermore, THZ1 synergized with gemcitabine and paclitaxel in vitro and in vivo, resulting in enhanced antitumor effects.Conclusions: Our findings support the application of CRISPR-Cas9 screening in identifying novel therapeutic targets and provide new strategies for overcoming chemoresistance in pancreatic cancer.
Diagnosis and Management of Invasive Candida Infections in Critically Ill Patients
Istambouli, Rachid , Jabbour, Jean-Francois , Zakhem, Aline El , Hindy, Joya-Rita , Gharamti, Amal A. , Kanj, Souha S.

Mayo Clinic

Seminars in Respiratory and Critical Care Medicine | February 16, 2022 | Volume: 43 | Issue: 01 | Pages: 046-059

10.1055/s-0041-1741009 | PMID 35172358 Get It

AbstractInvasive candidiasis (IC) has become a serious problem in the intensive care unit patients with an attributable mortality rate that can reach up to 51%. Multiple global surveillance studies have shown an increasing incidence of candidemia. Despite their limited sensitivity (21–71%), cultures remain the gold standard for the diagnosis of IC associated with candidemia. Many adjunct laboratory tests exist to support or rule out the diagnosis, each with its indications and limitations, including procalcitonin, 1,3-β-D-glucan, mannan and anti-mannan antibodies, and Candida albicans germ tube antibody. In addition, polymerase chain reaction-based methods could expedite species identification in positive blood cultures, helping in guiding early empirical antifungal therapy. The management of IC in critically ill patients can be classified into prophylactic, preemptive, empiric, and directed/targeted therapy of a documented infection. There is no consensus concerning the benefit of prophylactic therapy in critically ill patients. While early initiation of appropriate therapy in confirmed IC is an important determinant of survival, the selection of candidates and drug of choice for empirical systemic antifungal therapy is more controversial. The choice of antifungal agents is determined by many factors, including the host, the site of infection, the species of the isolated Candida, and its susceptibility profile. Echinocandins are considered initial first-line therapy agents. Due to the conflicting results of the various studies on the benefit of preemptive therapy for critically ill patients and the lack of robust evidence, the Infectious Diseases Society of America (IDSA) omitted this category from its updated guidelines and the European Society of Intensive Care Medicine (ESICM) and the Critically Ill Patients Study Group of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) do not recommend it.
Granulomatosis with Polyangiitis-Mimicking Advanced Gynecological Cancer: A Case Report and Systematic Review of the Literature
Pereira, Augusto , Magrina, Javier F. , Magtibay, Paul M. , Stamps, Beatriz G., Muñoz-Nuñez, Elena, Pérez‐Medina, Tirso , Perez-Medina, Tirso , Pereira Sánchez, Augusto

Mayo Clinic

Journal of Personalized Medicine | February 16, 2022 | Volume: 12 | Issue: 2 | Pages: 289

10.3390/jpm12020289 | PMID 35207776 Get It

(1) Background: Granulomatosis with polyangiitis (GPA) is a necrotizing vasculitis that mimics gynecologic cancer. In GPA patients, the genitourinary system is affected in <1%. The objective of the study was to provide a systematic review of the literature of GPA patients with gynecological involvement. (2) Methods: PubMed and Embase were searched from inception to July 2021 for GPA patients with gynecological involvement Medical Subject Headings (MeSH) and free-text terms. Exclusion criteria were other language, review articles, pregnancy, fertility, or male patients. Data were extracted on clinical evolution, symptoms, examinations findings, diagnosis delay, treatment, outcome, patient status, and follow-up. (3) Results: Seventeen studies included data from patients with GPA and primary or relapsed gynecological involvement. 68% of the authors of this review thought the patient had cancer. The main gynecological symptom is bleeding, but exclusive gynecologic symptomatology is rare (ENT: 63%, lungs: 44%, kidneys-urinary tract: 53%). GPA could affect all areas of the genital tract, but the most frequent location is the uterine cervix. Medical treatment for GPA is effective. (4) Conclusions: GPA of the female genital tract must be considered when biopsies of an ulcerated malignant-appearing cervical or vaginal mass are negative for malignancy even when they are unspecific. Rheumatology consultation is indicated.
The international penile advanced cancer trial (InPACT): The first phase III trial for squamous carcinoma of the penis with regional lymph node metastases.
Pettaway, Curtis A. , Nicholson, Steve , Pagliaro, Lance C. , Watkin, Nick , Barber, Jim, Trabulsi, Edouard J. , Rosen, Mark, Burnett, Stephanie, Yap, Christina , Hall, Emma , investigators, On behalf of the InPACT, Hall, Emma C , Yap, Christina , Spiess, Philippe E. , Carducci, Michael A. , Crook, Juanita , Branney, Peter , OXLEY, JON D. , Billingham, Lucinda Jane , Penegar, Steven , investigators, On behalf of the InPACT

Mayo Clinic

Journal of Clinical Oncology | February 16, 2022 | Volume: 40 | Issue: 6_suppl | Pages: TPS7-TPS7

10.1200/jco.2022.40.6_suppl.tps7 Get It

TPS7 Background: Penis cancer is a rare but potentially fatal disease. A limited body of evidence exists on which to base the majority of management decisions for patients with regional nodal metastases. Five-year survival for patients with a single involved inguinal lymph node treated with surgery alone is approximately 80%, whilst it ranges from 0 to 12% for patients with pelvic node involvement (N3). Additional strategies are required for the management regionally-advanced disease. InPACT (NCT02305654) aims to determine prospectively the relative benefits and sequencing of surgery, chemotherapy, and chemoradiotherapy in the management of patients with penis cancer who present with palpable or radiologically evident inguinal lymph node metastases. InPACT addresses the following questions: Is there a role for neoadjuvant therapy and, if so, which of the two options (chemotherapy or chemoradiotherapy) before surgery gives superior outcomes? Among patients whose inguinal node histology predicts a high risk of recurrence, does prophylactic pelvic lymph node dissection (PLND) plus chemoradiation to the inguinal and pelvic fields improve survival compared to chemoradiation alone? Methods: A Bayesian trial design aims to include a wide population of patients and incorporates two randomisations: InPACT-neoadjuvant and InPACT-pelvis. Participants are stratified by disease burden (extent of nodal involvement), by the presence or absence of high-risk radiological features, and by GFR. Participants with high disease burden where neoadjuvant treatment is thought to be indicated are randomised to neoadjuvant chemotherapy or neoadjuvant chemoradiotherapy. Participants with intermediate disease burden are randomised to one of 3 arms: Surgery alone or neoadjuvant chemoradiotherapy followed by surgery, or neoadjuvant chemotherapy prior to surgery. Participants in the low-burden group proceed directly to surgery. Participants with postoperative inguinal node pathology that shows high-risk features may then proceed to InPACT-pelvis where randomisation is between adjuvant chemoradiotherapy ± PLND for those not previously treated with chemoradiotherapy & between PLND & observation for those previously treated with neoadjuvant chemoradiotherapy. The study aims to recruit 200 participants. The primary outcome measure is overall survival, with secondary outcome measures of disease-specific survival, disease-free survival, and freedom from locoregional recurrence and distant metastasis. Feasibility, toxicity, the type/extent of surgical complications, and quality of life will be assessed as secondary endpoints for all the InPACT treatment arms. To October 2021, 65 participants have been recruited with centres open in the UK, US and Canada. Clinical trial information: NCT02305654.